BioNTech expects by September the trial results of the Covid-19 vaccine it developed with Pfizer for babies as young as six months old, according to German magazine Spiegel.
A trial published at the end of March found the companies’ Covid-19 vaccine was safe, effective and produces robust antibody responses in adolescents.
The Pfizer/BioNTech two-shot vaccine is already authorised for use in those aged 16 and above.